Latest Conference Articles

Early-onset drusen maculopathy (EODM), is part of the age-related macular degeneration (AMD) phenotype that occurs in individuals under 55 years of age.

SriniVas R. Sadda, MD, sat down with David Hutton of Ophthalmology Times to discuss his presentation about precursor lesions for development of atrophy and AMD from the Angiogenesis Exudation and Degeneration 2024 event.

Multimodal technology bridges the gap between advanced age-related macular degeneration (AMD) biomarkers and clinical features.

Bonnie An Henderson, MD, previews the EnVision Summit 2024, scheduled for February 16 to 19 in Puerto Rico, highlighting its family friendly atmosphere, diverse specialty coverage, and new sessions on leadership and health equity.

Roger A. Goldberg, MD, MBA, presents a post hoc analysis of the Phase 2/3 PHOTON trial, offering insights into the potential benefits of 8 mg aflibercept in managing fluid reaccumulation, particularly in cases of diabetic macular edema.

David A. Eichenbaum, MD, discusses the promising aspects of gene augmentation for treating common retinal diseases, addresses concerns about perpetual protein production, and considers the potential positive impact on patients by reducing treatment burdens.

David Eichenbaum, MD, discussed the status of the technology at the Retina 2024 meeting in Maui.

Glenn J. Jaffe, MD, discusses the multifactorial complexities of treating patients with geographic atrophy.

The Annual Gala will be held on February 8 from 6 to 9 pm Pacific Standard Time.

David Hutton of Ophthalmology Times talks with Eric Donnenfeld, MD about his presentation "Small Aperture IOL for Irregular Corneas" at this year's Hawaiian Eye and Retina 2024 Meeting.

David Hutton of Ophthalmology Times talks with William Trattler, MD, about his presentation "Toric IOL pearls for Correcting Lower Levels of Astigmatism" at this year's Hawaiian Eye and Retina 2024 Meeting.

Vascular compromise is the most ominous early adverse event that can occur when a filler is unintentionally injected into a blood vessel.

David Hutton of Ophthalmology Times talks with Andrew Lee, MD, about his presentation "Neuro op mimics of thyroid eye disease" at this year's Hawaiian Eye and Retina 2024 Meeting.

Company presenting data from the Phase II AAVIATE trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration January 16 at the Hawaiian Eye and Retina 2024 Meeting.

Sharing, learning, networking, collaborating

The Retina Program 2024 will convene during the Hawaiian Eye meeting in Maui from January 14 through January 19

Hawaiian Eye and Retina 2024 meetings will take place from January 13 to 19 at the Grand Wailea Maui, 3850 Wailea Alanui Drive, Wailea, HI.

David A. Eichenbaum, MD, highlighted new therapies such as faricimab and high-dose aflibercept to reduce the burden of diseases like macular degeneration and diabetic eye conditions while improving patient outcomes during his presentation at EyeCon 2023.

Moon Jeong Lee, MD, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, was honored as the recipient of the inaugural Visionary in Eye Care Resident Recognition Award for the category of Best in Ophthalmology during the EyeCon 2023 conference, December 1-2, at the Marriott Sanibel Harbour Resort and Spa in Sanibel, Florida.

Marta Stevanovic, MD, Massachusetts Eye and Ear, Harvard Medical School, Boston, was honored as the recipient of the inaugural Visionary in Eye Care Resident Recognition Award for the category of Best in Retina during the EyeCon 2023 conference, December 1-2, at the Marriott Sanibel Harbour Resort and Spa in Sanibel, Florida.

Analisa Arosemena, MD, underscores the importance of year-round glaucoma control through extended-release medications and laser treatments at EyeCon 2023.

Oluwatosin U. Smith, MD, and Peter J. McDonnell, MD, discuss their experience at EyeCon 2023, highlighting the latest updates in retina, cataract and refractive surgery, and the growing epidemic of myopia worldwide.

Jennifer Loh, MD, discusses the significance of maintaining a healthy ocular surface before surgery and exploring collaborative approaches for improved patient comanagement between ophthalmologists and optometrists at EyeCon 2023.

Mohammed Genead, MD, CEO of Aviceda spoke with the Ophthalmology Times team about the company's Phase II/III SIGLEC trial part 1 results, which were shared at this year's American Academy of Ophthalmology meeting.

Rob Thornhill, CEO of Centricity Vision spoke with the Ophthalmology Times team about the company's newest developments at this year's American Academy of Ophthalmology meeting.

Marco A. Zarbin, MD, spoke with the Ophthalmology Times team about conducting a post-hoc analysis of the YOSEMITE and RHINE clinical trials and presenting the results at this year's American Academy of Ophthalmology meeting.

Michael Rivers, MD, Senior Director of Ophthalmology at ModMed spoke with Modern Retina about their new single-screen initiative and the benefits it could have for saving time and simplifying communication within practices.

Diana Do, MD, spoke with the Ophthalmology Times team about her presentation of the results for the 96-week PHOTON study of aflibercept at this year's American Academy of Ophthalmology meeting.

Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualization and patients who've had small aperture IOL implantation at this year's American Academy of Ophthalmology meeting.

Charles Wykoff, MD, PhD, spoke with Ophthalmology Times about the GALE study data at one year looking at pegcetacoplan for the management of geographic atrophy at this year's American Academy of Ophthalmology meeting.